Medications
FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA
03/01/2019
(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among
Read More
